Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics reported Q2 2026 financial results and business updates highlighting progress in its CAR-T cell therapy pipeline targeting autoimmune diseases including myasthenia gravis, myositis, and juvenile dermatomyositis. The company secured a strategic licensing agreement with WestGene to develop an in vivo CAR-T platform, expects mul…